A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma
Journal
Anticancer Research
Journal Volume
38
Journal Issue
8
Date Issued
2018-08-01
Abstract
© 2018 International Institute of Anticancer Research. All rights reserved. Background/Aim: Radiotherapy is not routinely used in metastatic pancreatic ductal adenocarcinoma (PDAC). We conducted a phase I study to investigate concurrent chemoradiotherapy (CCRT) followed by chemotherapy. Materials and Methods: S-1 was administered at 50-70 mg/m2/day with radiotherapy in 2.5-3.6 Gy/day for 10-12 fractions. After CCRT, gemcitabine (1,000 mg/m2 on days 1 and 15) and S-1 (60-100 mg/day on days 1-7 and 15-21), were administered in a 4-week cycle. Results: After enrolling 10 patients, the study was terminated due to slow recruitment. Dose-limiting toxicities and maximum tolerated doses were not identified. Most patients experienced mild toxicities, including nausea, vomiting, and anorexia. One patient developed grade 3 infection. One patient achieved partial remission, while the remaining nine patients had stable disease, with a local disease control rate of 100% after CCRT. Conclusion: A short-course CCRT followed by chemotherapy was potentially feasible in patients with metastatic PDAC.
Subjects
Gemcitabine | Metastasis | Pancreatic ductal adenocarcinoma | Radiotherapy | S-1
Gemcitabine; Metastasis; Pancreatic ductal adenocarcinoma; Radiotherapy; S-1
SDGs
Other Subjects
gemcitabine; gimeracil plus oteracil potassium plus tegafur; antineoplastic agent; antineoplastic antimetabolite; CA 19-9 antigen; deoxycytidine; gemcitabine; oteracil; S 1 (combination); tegafur; adult; aged; anemia; anorexia; Article; cancer combination chemotherapy; cancer control; cancer regression; chemoradiotherapy; clinical article; diarrhea; drug safety; fatigue; feasibility study; female; human; infection; liver disease; male; middle aged; multiple cycle treatment; nausea; pancreas adenocarcinoma; phase 1 clinical trial; priority journal; radiation dose fractionation; radiotherapy dosage; treatment outcome; vomiting; analogs and derivatives; blood; chemoradiotherapy; clinical trial; disease free survival; drug combination; maximum tolerated dose; pancreas carcinoma; pathology; procedures; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome
Type
journal article